Literature DB >> 19878217

Cisplatin compromises myocardial contractile function and mitochondrial ultrastructure: role of endoplasmic reticulum stress.

Heng Ma1, Kyla R Jones, Rui Guo, Peisheng Xu, Youqing Shen, Jun Ren.   

Abstract

1. Cisplatin is a potent chemotherapeutic agent with broad-spectrum antineoplastic activity against various types of tumours. However, a major factor limiting treatment with cisplatin is its acute and cumulative cardiotoxicity. The aim of the present study was to explore the effect of cisplatin on myocardial contractile function and the possible underlying cellular mechanisms. 2. C57 mice were treated with cisplatin (10 mg/kg per day, i.v.) or vehicle (0.9% NaCl) for 1 week and myocardial function was assessed using the Langendorff and cardiomyocyte edge-detection systems. Transmission electron microscopy, mitochondrial membrane potential, indices of endoplasmic reticulum (ER) stress and caspase 3 activity were evaluated. 3. Cisplatin-treated mice developed myocardial contractile dysfunction, as evidenced by a reduction in left ventricular developed pressure (LVDP) and the first derivative of LVDP (+/-dP/dt). Cisplatin treatment significantly prolonged time to 90% relengthening, depressed peak shortening, maximal velocity of shortening/relengthening (+/-dL/dt) and augmented the frequency-elicited depression in peak shortening. The JC-1 fluorescent assay demonstrated that cispatin-induced cardiac dysfunction was associated with mitochondrial membrane depolarization. Transmission electron microscopy revealed that cisplatin induces ultrastructural abnormalities of the mitochondria. Following cisplatin treatment, cardiomyocytes show activation of the ER stress response, increased caspase 3 activity and increased terminal deoxyribonucleotidyl transferase-mediated dUTP-digoxigenin nick end-labelling (TUNEL) staining. 4. The data indicate that cisplatin is cardiotoxic and may lead to left ventricular dysfunction and depressed cardiomyocyte contraction associated with mitochondrial abnormalities, enhanced ER stress and apoptosis. This work should shed some light on the management of cisplatin-induced cardiac injury.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19878217     DOI: 10.1111/j.1440-1681.2009.05323.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  22 in total

1.  Kaempferol attenuated cisplatin-induced cardiac injury via inhibiting STING/NF-κB-mediated inflammation.

Authors:  Yajun Qi; Yin Ying; Jie Zou; Qilu Fang; Xiaohong Yuan; Yingying Cao; Yunfang Cai; Shuang Fu
Journal:  Am J Transl Res       Date:  2020-12-15       Impact factor: 4.060

2.  Mussel-inspired PLGA/polydopamine core-shell nanoparticle for light induced cancer thermochemotherapy.

Authors:  Huacheng He; Eleni Markoutsa; Yihong Zhan; Jiajia Zhang; Peisheng Xu
Journal:  Acta Biomater       Date:  2017-07-05       Impact factor: 8.947

Review 3.  Lung cancer as a cardiotoxic state: a review.

Authors:  David Pérez-Callejo; María Torrente; María Auxiliadora Brenes; Beatriz Núñez; Mariano Provencio
Journal:  Med Oncol       Date:  2017-08-09       Impact factor: 3.064

Review 4.  Drug-induced mitochondrial dysfunction and cardiotoxicity.

Authors:  Zoltán V Varga; Peter Ferdinandy; Lucas Liaudet; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-09-18       Impact factor: 4.733

5.  Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity.

Authors:  Md Abdul Hye Khan; Jing Liu; Ganesh Kumar; Stephen X Skapek; John R Falck; John D Imig
Journal:  FASEB J       Date:  2013-04-19       Impact factor: 5.191

6.  A novel clinical indicator using cardiac technetium-99m sestamibi kinetics for evaluating cardiotoxicity in cancer patients treated with multiagent chemotherapy.

Authors:  Gian Piero Carboni
Journal:  Am J Cardiovasc Dis       Date:  2012-10-25

7.  Cisplatin and cisplatin analogues perfusion through isolated rat heart: the effects of acute application on oxidative stress biomarkers.

Authors:  Isidora M Stojic; Vladimir I Zivkovic; Ivan M Srejovic; Tamara R Nikolic; Nevena S Jeremic; Jovana N Jeremic; Dragan M Djuric; Nemanja Jovicic; Katarina G Radonjic; Zivadin D Bugarcic; Vladimir L J Jakovljevic; Slobodan S Novokmet
Journal:  Mol Cell Biochem       Date:  2017-08-01       Impact factor: 3.396

Review 8.  A new strategy of promoting cisplatin chemotherapeutic efficiency by targeting endoplasmic reticulum stress.

Authors:  Ye Xu; Chunyan Wang; Zhixin Li
Journal:  Mol Clin Oncol       Date:  2013-10-18

9.  Molecular docking, pharmacokinetic studies, and in vivo pharmacological study of indole derivative 2-(5-methoxy-2-methyl-1H-indole-3-yl)-N'-[(E)-(3-nitrophenyl) methylidene] acetohydrazide as a promising chemoprotective agent against cisplatin induced organ damage.

Authors:  Suhail Razak; Tayyaba Afsar; Nousheen Bibi; Mahmoud Abulmeaty; Wajhul Qamar; Ali Almajwal; Anam Inam; Dara Al Disi; Maria Shabbir; Mashooq Ahmad Bhat
Journal:  Sci Rep       Date:  2021-03-18       Impact factor: 4.379

10.  Mitophagy Impairment Aggravates Cisplatin-Induced Ototoxicity.

Authors:  Sung Il Cho; Eu-Ri Jo; Hansoo Song
Journal:  Biomed Res Int       Date:  2021-05-20       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.